Literature DB >> 23734943

Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation.

Robert K Brooner1, Michael S Kidorf, Van L King, Jessica Peirce, Karin Neufeld, Ken Stoller, Ken Kolodner.   

Abstract

BACKGROUND AND AIMS: Integrating psychiatric services within substance abuse treatment settings is a promising service delivery model, but has not been evaluated using random assignment to psychiatric treatment setting and controlled delivery of psychiatric care. This study evaluates the efficacy of on-site and integrated psychiatric service delivery in an opioid-agonist treatment program on psychiatric and substance use outcomes.
DESIGN: Participants at the Addiction Treatment Services (ATS) were assigned randomly to receive on-site and integrated substance abuse and psychiatric care (on-site: n = 160) versus off-site and non-integrated substance abuse and psychiatric care (off-site: n = 156), and observed for 1 year. On-site participants received all psychiatric care within the substance abuse program by the same group of treatment providers. The same type and schedule of psychiatric services were available to off-site participants at a community psychiatry program.
SETTING: All participants received routine methadone maintenance at the ATS program in Baltimore, Maryland, USA. PARTICIPANTS: Participants were opioid-dependent men and women with at least one comorbid psychiatric disorder, as assessed by the Structured Clinical Interview for DSM-IV and confirmed by expert clinical reappraisal. MEASUREMENTS: Outcomes included psychiatric service utilization and retention, Hopkins Symptom Checklist Global Severity Index (GSI) change scores and urinalysis test results.
FINDINGS: On-site participants were more likely to initiate psychiatric care 96.9 to 79.5%; P < 0.001), remain in treatment longer (195.9 versus 101.9 days; P < 0.001), attend more psychiatrist appointments (12.9 versus 2.7; P < 0.001) and have greater reductions in GSI scores (4.2 versus 1.7; P = 0.003) than off-site participants; no differences were observed for drug use.
CONCLUSIONS: On-site and integrated psychiatric and substance misuse services in a methadone treatment setting might improve psychiatric outcomes compared with off-site and non-integrated substance misuse and psychiatric care. However, this might not translate into improved substance misuse outcomes.
© 2013 Society for the Study of Addiction.

Entities:  

Keywords:  Drug use; integrated care; methadone maintenance; psychiatric care; psychiatric comorbidity; treatment response

Mesh:

Substances:

Year:  2013        PMID: 23734943      PMCID: PMC3833440          DOI: 10.1111/add.12269

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  33 in total

Review 1.  Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials.

Authors:  Maria Donald; Jo Dower; David Kavanagh
Journal:  Soc Sci Med       Date:  2005-03       Impact factor: 4.634

2.  Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence.

Authors:  Robert K Brooner; Michael S Kidorf; Van L King; Kenneth B Stoller; Karin J Neufeld; Ken Kolodner
Journal:  Drug Alcohol Depend       Date:  2007-01-24       Impact factor: 4.492

3.  Responding to the challenge of co-occurring disorders: suggestions for future research.

Authors:  Stanley Sacks; Redonna Chandler; Junius Gonzales
Journal:  J Subst Abuse Treat       Date:  2007-06-15

4.  Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial.

Authors:  James L Sorensen; Nancy A Haug; Kevin L Delucchi; Valerie Gruber; Evan Kletter; Steven L Batki; Jacqueline P Tulsky; Paul Barnett; Sharon Hall
Journal:  Drug Alcohol Depend       Date:  2006-10-23       Impact factor: 4.492

5.  Addiction treatment services and co-occurring disorders: Prevalence estimates, treatment practices, and barriers.

Authors:  Mark P McGovern; Haiyi Xie; Sam R Segal; Lauren Siembab; Robert E Drake
Journal:  J Subst Abuse Treat       Date:  2006-07-24

6.  Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial.

Authors:  E V Nunes; F M Quitkin; S J Donovan; D Deliyannides; K Ocepek-Welikson; T Koenig; R Brady; P J McGrath; G Woody
Journal:  Arch Gen Psychiatry       Date:  1998-02

7.  Psychiatric and substance use comorbidity among treatment-seeking opioid abusers.

Authors:  R K Brooner; V L King; M Kidorf; C W Schmidt; G E Bigelow
Journal:  Arch Gen Psychiatry       Date:  1997-01

8.  Unmet needs for comprehensive services in outpatient addiction treatment.

Authors:  Janice L Pringle; Nicholas P Emptage; Robert L Hubbard
Journal:  J Subst Abuse Treat       Date:  2006-04

Review 9.  A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders.

Authors:  Robert E Drake; Erica L O'Neal; Michael A Wallach
Journal:  J Subst Abuse Treat       Date:  2007-06-15

10.  A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.

Authors:  Alan S Bellack; Melanie E Bennett; Jean S Gearon; Clayton H Brown; Ye Yang
Journal:  Arch Gen Psychiatry       Date:  2006-04
View more
  15 in total

1.  Classifying substance use disorder treatment facilities with co-located mental health services: A latent class analysis approach.

Authors:  Pia M Mauro; C Debra Furr-Holden; Eric C Strain; Rosa M Crum; Ramin Mojtabai
Journal:  Drug Alcohol Depend       Date:  2016-04-07       Impact factor: 4.492

Review 2.  The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight.

Authors:  Joseph K Eibl; Kristen Morin; Esa Leinonen; David C Marsh
Journal:  Can J Psychiatry       Date:  2017-05-19       Impact factor: 4.356

3.  Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States.

Authors:  Marcus A Bachhuber; William N Southern; Chinazo O Cunningham
Journal:  Med Care       Date:  2014-05       Impact factor: 2.983

4.  Comparison of methods to assess psychiatric medication adherence in methadone-maintained patients with co-occurring psychiatric disorder.

Authors:  Kelly E Dunn; Van L King; Robert K Brooner
Journal:  Drug Alcohol Depend       Date:  2016-01-30       Impact factor: 4.492

5.  Substance use and response to psychiatric treatment in methadone-treated outpatients with comorbid psychiatric disorder.

Authors:  Michael Kidorf; Van L King; Jessica Peirce; Neeraj Gandotra; Sharon Ghazarian; Robert K Brooner
Journal:  J Subst Abuse Treat       Date:  2014-11-05

6.  Effect of traumatic event reexposure and PTSD on substance use disorder treatment response.

Authors:  Jessica M Peirce; Robert K Brooner; Van L King; Michael S Kidorf
Journal:  Drug Alcohol Depend       Date:  2015-11-21       Impact factor: 4.492

7.  Challenges and outcomes of parallel care for patients with co-occurring psychiatric disorder in methadone maintenance treatment.

Authors:  Van L King; Robert K Brooner; Jessica Peirce; Ken Kolodner; Michael Kidorf
Journal:  J Dual Diagn       Date:  2014

Review 8.  Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist.

Authors:  Kinna Thakarar; Zoe M Weinstein; Alexander Y Walley
Journal:  Postgrad Med J       Date:  2016-03-22       Impact factor: 2.401

9.  Factors Associated with Symptoms of Depression among Injection Drug Users Receiving Antiretroviral Treatment in Indonesia.

Authors:  Yi Li; Ronald Hershow; Ignatius Praptoraharjo; Made Setiawan; Judith Levy
Journal:  J AIDS Clin Res       Date:  2014-05-01

10.  Psychosocial interventions for people with both severe mental illness and substance misuse.

Authors:  Glenn E Hunt; Nandi Siegfried; Kirsten Morley; Carrie Brooke-Sumner; Michelle Cleary
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.